Table 2.
Changes in the anthropometric and clinical variables at 1 and 6 months after starting liraglutide treatment.
| Variable | Enrolment | 1 Month | 6 Months | p for Trend ^ |
|---|---|---|---|---|
| Number | 19 | 19 | 19 | |
| Weight (kg) | 60.3 ± 18.0 | 61.3 ± 18.1 | 62.8 ± 16.6 | 0.10 |
| BMI (kg/m2) | 21.9 ± 7.3 | 22.1 ± 7.3 | 22.5 ± 6.8 | 0.37 |
| Free-fat mass (kg) | 25.6 ± 6.3 | 27.2 ± 8.2 | 27.6 ± 7.4 * | 0.23 |
| Cellular mass (kg) | 20.0 ± 5.3 | 21.4 ± 7.1 | 22.2 ± 6.3 * | 0.24 |
| Phase angle (degrees) | 4.6 ± 1.0 | 4.8 ± 1.5 | 4.9 ± 1.0 | 0.51 |
| Stomal/fecal output (mL/day) † | 2500.0 (1750.0) | 2000.0 (2000.0) | 1500.0 (1800.0) § | 0.039 |
| Urinary output (mL/day) | 1450.0 ± 603.9 | 1678.9 ± 817.1 | 1365.8 ± 662.1 | 0.36 |
| Urinary sodium (mmol/day) † | 59.0 (92.0) | 66.0 (182.0) | 116.0 (184.0) | 0.17 |
| Total volume infused (mL/day) | 2478.3 ± 1022.7 | 2342.1 ± 1101.3 | 2166.4 ± 1308.5 | 0.35 |
| Fluid, oral intake (mL/day) | 2139.5 ± 835.1 | 2113.2 ± 958.6 | 1836.8 ± 705.9 | 0.32 |
| Energy, parenteral supply (kcal/day) | 1310.5 ± 593.7 | 1121.2 ± 480.9 | 927.3 ± 597.8 * | 0.007 |
| Number of nights/week of parenteral supply (%) | ||||
| 7 | 84.2 | 68.4 | 63.2 § | 0.018 |
| 6 | 0 | 5.3 | 5.3 | |
| 5 | 15.8 | 21.1 | 15.8 | |
| 4 | 0 | 0 | 5.3 | |
| 3 | 0 | 5.3 | 5.3 | |
| 0 | 0 | 0 | 5.3 | |
| Energy, oral intake (kcal/day) | 1965.7 ± 1335.9 | 1680.0 ± 806.0 | 1730.8 ± 537.4 | 0.41 |
| Serum albumin (g/dL) | 3.2 ± 0.5 | 4.1 ± 0.6 ** | 4.0 ± 0.6 ** | <0.001 |
| Serum transferrin (mg/dL) | 202.1 ± 50.0 | 272.5 ± 76.6 ** | 258.2 ± 83.8 ** | <0.001 |
| Serum pre-albumin (g/dL) | 22.3 ± 7.1 | 29.4 ± 9.1 ** | 27.1 ± 5.9 * | 0.004 |
^ p by one-way repeated measures ANOVA or by Friedman ANOVA. * p < 0.05 by paired t-test with respect to baseline values; ** p < 0.01 by paired t-test with respect to baseline values. † median (interquartile range) for non-normally distributed variables. § p < 0.05 by Wilcoxon matched-pairs test with respect to baseline values.